Article content continued

Collaboration Between Panaxia Pharmaceuticals & Rafa Pharmaceuticals

Recently, Israeli scientists have focused their efforts on creating the most effective and beneficial cannabis inhaler possible with the intent to help people with not only acute and chronic cancer-causing pain but also those with respiratory problems. Even though consuming cannabis through an inhaler is a new way to use the herb, this method is still being tested to ensure that all kinks will be resolved before the public has access to this product.

The two Israeli companies that have collaborated with each other and already got the ball rolling are Panaxia Pharmaceuticals and Rafa Pharmaceuticals. Then, not long ago, Panaxia released information about the operation of new clinical trials at the country’s Ministry of Health. The intention of conducting clinical trials is to get a better understanding about the bioavailability of cannabis via inhalers with accurately measured controlled doses.

Photo by Gavin Young/Postmedia

If you know someone who might benefit from cannabis inhalers, registration for these clinical trials are now open. According to Dr. Dadi Segal, Panaxia’s CEO, the following was stated about cannabis inhalers and the product’s clinical trials:

“The clinical trial is performed as part of the registration procedure of the new products, which we are about to launch in Israel this year in collaboration with Rafa. Through access to cannabis inhalers, and subject to a medical specialist’s recommendation, we strive to help more patients suffering from acute pain. The inhaler will provide patients that are unable or unwilling to smoke the right to be treated consistently and precisely.”